Cirrhosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
This is an end stage disease. There is no cure and Homeopathy tries to palliate its complications | This is an end stage disease. There is no cure and Homeopathy tries to palliate its complications | ||
== Remedies == | |||
* [[Crot-h, Crotalus horridus|Crot-h]] | * [[Crot-h, Crotalus horridus|Crot-h]] | ||
* [[Sul-ac, Sulphuric acid|Sul-ac]] | * [[Sul-ac, Sulphuric acid|Sul-ac]] | ||
| Line 11: | Line 10: | ||
=== [[Banerji protocols]] === | === [[Banerji protocols]] === | ||
|- | |- | ||
|First line | |'''First line''' | ||
| | | | ||
* Chel 6X + Lyc C30 one dose every 3 hour alternately | * [[Chel, Chelidonium|Chel]] 6X + [[Lyc , Lycopodium clavatum|Lyc]] C30 one dose every 3 hour alternately | ||
|- | |- | ||
|Second line | |'''Second line''' | ||
| | | | ||
* Chel 6X + Lyc C30 one dose every 3 hour alternately | * [[Chel, Chelidonium|Chel]] 6X + [[Lyc , Lycopodium clavatum|Lyc]] C30 one dose every 3 hour alternately | ||
* Myrica 0 three doses daily | * [[Myrica, Myrica cerifera|Myrica]] 0 three doses daily | ||
|- | |- | ||
|Third line | |'''Third line''' | ||
| | | | ||
* Chel 6X + Lyc C30 one dose every 3 hour alternately | * [[Chel, Chelidonium|Chel]] 6X + [[Lyc , Lycopodium clavatum|Lyc]] C30 one dose every 3 hour alternately | ||
* Myrica 0 three doses daily | * [[Myrica, Myrica cerifera|Myrica]] 0 three doses daily | ||
* Acetic | * [[Acet-ac, Acetic Acidum|Acet-ac]] C30 TDS for resistant [[ascites]] | ||
|} | |} | ||
=== [[Tissue Salt Remedies]] === | === [[Tissue Salt Remedies]] === | ||
* KP | * [[KP, Tissue Salt Remedy|KP]] | ||
* SIL | * [[SIL, Tissue Salt Remedy|SIL]] | ||
Latest revision as of 10:24, 14 November 2023
This is an end stage disease. There is no cure and Homeopathy tries to palliate its complications
Remedies
Banerji protocols | |
|---|---|
| First line | |
| Second line | |
| Third line | |